Abstract:It has been demonstrated that anti-PD-1 immunotherapy may have potentially life-threatening side effect (i.e., autoimmune myocarditis with consequent cardiac failure). The purpose of this work was to determine the incidence and severity of radiation-induced cardiac mortality and morbidity in a murine model when cardiac irradiation is delivered concurrently with an anti-PD-1 antibody. Single fraction (20 Gy) was delivered specifically to the heart of female C57bl/6 mice with an image-guided SARRP, which allows on-board micro-CT imaging and real-time treatment planning. Mice were stratified into 4 treatment groups: (1) control IgG (n = 10); (2) anti-PD1 antibody (n = 10); (3) RT+ control IgG (n = 20); and (4) RT + anti-PD1 antibody (n = 20). Anti-CD4 and anti-CD8 antibodies were combined with RT and anti-PD1 antibody treatment to deplete subsets of T cells. Antibodies were intraperitoneally administrated 24 hours before of RT, and then every other day. Overall survival was determined. Echocardiographic assessment on all mice was performed to measure the cardiac contraction and output when clinical morbidity was encountered. The sick mice were then sacrificed for tissue collections, which were characterization by immunofluorescence for immune cells infiltration. Decreased survival was observed when anti-PD-1 was combined with RT: 35% (7/20) mortality vs. 0% mortality in other three groups (P < 0.05). The median survival following RT in the RT + Anti-PD1 group was day 8 (day 5 to 19). Ejection fraction (EF) and fractional shortening (FS) were used to measure cardiac function. Combined therapy group exhibited significantly decline in both EF and FS, especially compared with mice treated with RT + IgG control: the EFs of group 1 to 4: 62.43% ± 7.54%, 60.19% ± 5.81%, 50.85% ± 5.06%, and 38.84% ± 6.06%, P < 0.01; the FSs: 33.48% ± 5.48%, 31.66% ± 4.09%, 25.50% ± 3.13%, and 18.58% ± 3.28%, P < 0.01. These data indicates that 20 Gy induced cardiac dysfunction, which was exacerbates by anti-PD1 treatment. Myocarditis was observed in the dying mice after RT. Further immunologic data on heart tissue changed showed increased tumor infiltration by CD45, CD3, CD4, and CD8. Consistent with worse cardiac dysfunction, considerably more immune cells were observed in heart tissues of the dying mice from RT+ anti-PD1 compared with those from RT plus control IgG. To test which subset of T cells contributes to the myocarditis, neutralizing antibodies against CD4 and CD8 were combined with RT and anti-PD1 treatment. Consistently, depletion of CD8 T cells prevented mortality from RT plus anti-PD1 whereas depletion of CD4 did not, indicating that CD8+ lymphocytes mediates cardiac injury from RT + anti-PD1. The combination of PD-1 blockade increases the cardiac toxicity from irradiation through cytotoxic T cell-mediated myocarditis. Our study provides strong preclinical evidence that immune-related adverse events should be considered when PD-1 inhibitor is combined with RT.

PD-1 Inhibitor Aggravate Irradiation-Induced Myocardial Fibrosis by Regulating TGF-β1/Smads Signaling Pathway via GSDMD-Mediated Pyroptosis

Pharmacological Inhibition of PD-1 Exacerbates Radiation-Induced Cardiac Toxicity Through Cytotoxic T Cell–Mediated Myocarditis

PD-1 Modulates Radiation-Induced Cardiac Toxicity Through Cytotoxic T Lymphocytes.

Radiation-induced myocardial fibrosis: Mechanisms underlying its pathogenesis and therapeutic strategies

Effect of PD-1 Inhibitor Combined with X-Ray Irradiation on the Inflammatory Microenvironment and Lung Tissue Injury in Mice

GSDMD-Mediated Cardiomyocyte Pyroptosis Promotes Myocardial I/R Injury

Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation

Pyrrolidine Dithiocarbamate Might Mitigate Radiation-Induced Heart Damage at an Early Stage in Rats

Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling

PDTC Attenuates Radiation Induced Heart Damage Through Inhibition of Activation of NF-κB and Its Downstream Pathway in Rats

[Investigate the Role of Neutrophil Extracellular Traps in Immune Checkpoint Inhibitor-Associated Myocarditis with Programmed Death Protein-1 Inhibitors Involvement].

Study on the Mechanism of Ginsenoside Rg5 Attenuating Radiation Myocarditis Through GDF11-SIRT1 Pathway.

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction

Endor exacerbates the development of radiation myocardial fibrosis through the tgf-b1/smad signalling pathway

Pyroptosis in Myocardial Ischemia/reperfusion and Its Therapeutic Implications

Pathogenesis and Prevention of Radiation-induced Myocardial Fibrosis

Role of PDGFR-β/PI3K/AKT Signaling Pathway in PDGF-BB Induced Myocardial Fibrosis in Rats.

Cardiac fibroblast heat shock protein 47 aggravates cardiac fibrosis post myocardial ischemia–reperfusion injury by encouraging ubiquitin specific peptidase 10 dependent Smad4 deubiquitination

Radiation-induced Heart Energy Metabolism Dysfunction Leads to Heart Fibrosis

PD-1 restrains IL-17A production from γδ T cells to modulate acute radiation-induced lung injury

Iguratimod Alleviates Myocardial Ischemia/Reperfusion Injury Through Inhibiting Inflammatory Response Induced by Cardiac Fibroblast Pyroptosis via COX2/NLRP3 Signaling Pathway